1. Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results 
Joseph Pidala, Jongphil Kim, Brian C. Betts, Melissa Alsina, Ernesto Ayala, Hugo F. Fernandez, Teresa Field, Mohamed A. Kharfan- Dabaja, Frederick L. Locke, Asmita Mishra, Taiga Nishihori, Leonel Ochoa-Bayona, Lia Perez, Marcie Riches, Claudio Anasetti 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 6, Pages (June 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Reduction in systemic glucocorticoid therapy during study period. Box plots present median values and whiskers present minimum-maximum range.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Change in chronic GVHD severity. (A) Indicates distribution of NIH global 0 to 3 scores at baseline, 3 months, and 6 months. (B) Indicates change in global NIH 0 to 3 score from baseline to 6 months separately for those with initial score 2 (top) versus 3 (bottom). (C) Indicates clinician-reported overall response category at 3 months (top) and 6 (bottom) months.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3 Ofatumumab therapy depletes total CD19+ B cells and IgG.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions